Intracellular Retention of ABL Kinase Inhibitors Determines Commitment to Apoptosis in CML Cells

Clinical development of imatinib in CML established continuous target inhibition as a paradigm for successful tyrosine kinase inhibitor (TKI) therapy. However, recent reports suggested that transient potent target inhibition of BCR-ABL by high-dose TKI (HD-TKI) pulse-exposure is sufficient to irreve...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipka, Daniel B., Wagner, Marie-Christine, Dziadosz, Marek, Schnöder, Tina, Heidel, Florian, Schemionek, Mirle, Melo, Junia V., Kindler, Thomas, Müller-Tidow, Carsten, Koschmieder, Steffen, Fischer, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3397954/
https://www.ncbi.nlm.nih.gov/pubmed/22815843
http://dx.doi.org/10.1371/journal.pone.0040853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3397954/
https://www.ncbi.nlm.nih.gov/pubmed/22815843
http://dx.doi.org/10.1371/journal.pone.0040853

Ejemplares similares